HC Wainwright Brokers Increase Earnings Estimates for NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Research analysts at HC Wainwright increased their Q2 2025 earnings estimates for shares of Nurix Therapeutics in a note issued to investors on Tuesday, July 1st. HC Wainwright analyst R. Burns now expects that the company will earn ($0.62) per share for the quarter, up from their prior estimate of ($0.74). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.84) EPS and Q4 2026 earnings at ($0.87) EPS.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company reduced their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Leerink Partners started coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They set a “market perform” rating and a $16.00 target price for the company. Stifel Nicolaus reduced their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Needham & Company LLC reissued a “buy” rating and set a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Finally, Leerink Partnrs raised shares of Nurix Therapeutics to a “hold” rating in a research report on Monday, March 17th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.18.

Nurix Therapeutics Stock Up 2.3%

Nurix Therapeutics stock opened at $12.73 on Thursday. Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $29.56. The firm has a 50 day moving average price of $11.12 and a 200-day moving average price of $14.10. The company has a market capitalization of $970.54 million, a P/E ratio of -4.55 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. The business had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period in the prior year, the firm posted ($0.76) EPS.

Insider Buying and Selling

In related news, insider Gwenn Hansen sold 3,377 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider directly owned 61,516 shares in the company, valued at approximately $707,434. This represents a 5.20% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of the company’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the sale, the chief financial officer owned 33,724 shares in the company, valued at $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,013 shares of company stock worth $137,096 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Nurix Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Jump Financial LLC purchased a new stake in Nurix Therapeutics in the 4th quarter worth approximately $1,406,000. Affinity Asset Advisors LLC lifted its stake in Nurix Therapeutics by 9.3% in the 4th quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company’s stock worth $17,711,000 after purchasing an additional 79,684 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Nurix Therapeutics in the 4th quarter worth approximately $1,026,000. RA Capital Management L.P. purchased a new stake in Nurix Therapeutics in the 4th quarter worth approximately $25,120,000. Finally, Norges Bank purchased a new stake in Nurix Therapeutics in the 4th quarter worth approximately $6,006,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.